Clinical Trials - April 29, 2014
Adenovir starts phase II clinical study
The Swedish pharmaceutical development company Adenovir Pharma has started a phase II clinical study for the treatment of an infectious eye disease. Adenovir has already completed a clinical phase I study among 48 healthy volunteers and showed that the drug candidate is safe and well tolerated. The company is now continuing the development of a pharmaceutical […]
Agreement - April 25, 2014
Bactiguard expands in Latin America
The company has signed a distribution agreement with Promedon allowing the company to sell Bactiguard’s complete portfolio of medical devices in Argentina, Brazil, Chile and Mexico. Under the agreement, Promedon will be marketing and selling Bactiguard’s complete portfolio for infection control, including urinary, intravenous and respiratory catheters in the four countries. According to Bactiguard, the company has already secured […]
Pharma Business - April 23, 2014
Nanologica creates spin-off company
The Swedish high-tech company Nanologica spins off its asset within obesity into a standalone business distributed to the company’s shareholders with Sana Alajmovic serving as CEO. According to an announcement the spin-off is done to speed up development of a new medical product for the treatment of obesity. The new company will go under the name […]
Acquisition - April 22, 2014
Novartis buys GSK oncology unit
GlaxoSmithKline has announced a 3-part inter-conditional transaction with Novartis AG involving its Consumer Healthcare, Vaccines and Oncology businesses. The two companies will create a new consumer healthcare business with 2013 pro forma revenues of £6.5 billion. GSK will have majority control with an equity interest of 63.5%. GSK will also acquire Novartis’ global Vaccines business (excluding […]
Clinical Trials - April 17, 2014
Abbvie presents results from hepatitis C study
Abbvie presents new, detailed results from its hepatitis C development program. TURQUOISE-II is a global, multi-center, randomized, open-label study evaluating the efficacy and safety of 12 weeks or 24 weeks of treatment with AbbVie’s regimen with ribavirin (RBV) in adult patients with genotype 1 (GT1) chronic hepatitis C virus (HCV) infection with compensated liver cirrhosis. Patients […]
Uncategorized - April 17, 2014
New findings on prostate cancer treatment
Rigshospitalet in Denmark has developed a new type of treatment using alpha rays in liquid form which has fewer side-effects and means better chances of survival for patients with prostate cancer. The substance is injected into the arteries through a venflon catheter and then it flows around with the blood and becomes trapped in the […]
